Analysis
Dare Bioscience, a clinical-stage women's health biopharmaceutical company, filed a new S-1 registration statement with the SEC on August 26, 2026, according to the filing. The filing follows a securities purchase agreement Dare entered on August 14 with institutional investors for a concurrent private placement and registered direct offering.
The Raise
That offering closed August 17, netting the company approximately $5.3 million from the sale of 4,085,687 shares of common stock and pre-funded warrants to purchase up to an additional 293,894 shares. Alongside the share sale, Dare issued Series A and Series B warrants covering up to roughly 4.38 million shares each -- a warrant-heavy structure typical of small-cap biopharma financings, where investors demand extra upside protection in exchange for funding a company still years from broad profitability. Dare's stock, which trades on the Nasdaq Capital Market under the ticker DARE, closed at $0.80 per share on August 24, a price level that leaves the company exposed to further dilution risk with each successive raise.
“Until that data lands, expect the company's S-1 and warrant-registration cadence to continue roughly in step with its cash burn.”
What Dare Actually Sells
Dare's commercial footprint currently rests on a single approved product: XACIATO, a clindamycin phosphate vaginal gel for bacterial vaginosis, which is licensed globally to Organon and has been available nationwide in the U.S. since early 2024. Everything else in Dare's portfolio is still in clinical development -- most notably Ovaprene, a hormone-free monthly intravaginal contraceptive licensed to Bayer for U.S. commercialization, which is now in a pivotal Phase 3 study. The pipeline also includes Sildenafil Cream, 3.6%, targeting female sexual arousal disorder, and DARE-HRT1, a combination estradiol-progesterone intravaginal ring for menopausal hormone therapy.
The Funding Gap Behind the Filing
A company earning royalty and milestone revenue from one licensed, approved product while running Phase 3 trials on its lead pipeline asset is a familiar small-cap biopharma pattern -- and it's exactly the setup that produces a steady cadence of dilutive raises like this one. Bayer's license on Ovaprene means Dare isn't funding the full Phase 3 program alone, but the company's own SEC disclosures have flagged going-concern-adjacent cash constraints in recent quarters, making raises like the August offering less a growth signal than a runway-extension necessity.
What to Watch
The Ovaprene Phase 3 readout is the single event most likely to reprice DARE stock meaningfully in either direction -- a positive result would validate Bayer's license and could support a much larger financing on better terms, while a disappointing one would leave Dare leaning further on XACIATO royalties alone. Until that data lands, expect the company's S-1 and warrant-registration cadence to continue roughly in step with its cash burn.
